Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2019 Nov 13;9(63):36890-36906.
doi: 10.1039/c9ra07127j. eCollection 2019 Nov 11.

Protein-lipid complexes: molecular structure, current scenarios and mechanisms of cytotoxicity

Affiliations
Review

Protein-lipid complexes: molecular structure, current scenarios and mechanisms of cytotoxicity

Esmail M El-Fakharany et al. RSC Adv. .

Abstract

Some natural proteins can be complexed with oleic acid (OA) to form an active protein-lipid formulation that can induce tumor-selective apoptosis. The first explored protein was human milk α-lactalbumin (α-LA), called HAMLET when composed with OA in antitumor form. Several groups have prepared active protein-lipid complexes using a variety of approaches, all of which depend on target protein destabilization or direct OA-protein incubation to alter pH to acid or alkaline condition. In addition to performing vital roles in inflammatory processes and immune responses, fatty acids can disturb different metabolic pathways and cellular signals. Therefore, the tumoricidal action of these complexes is related to OA rather than the protein that keeps OA in solution and acts as a vehicle for transferring OA molecules to tumor cells. However, other studies have suggested that the antitumor efficacy of these complexes was exerted by both protein and OA together. The potential is not limited to the anti-tumor activity of protein-lipid complexes but extends to other functions such as bactericidal activity. The protein shell enhances the solubility and stability of the bound fatty acid. These protein-lipid complexes are promising candidates for fighting various cancer types and managing bacterial and viral infections.

PubMed Disclaimer

Conflict of interest statement

The authors declare that there is no conflict of interest regarding the publication of this manuscript.

Figures

Fig. 1
Fig. 1. Protein–lipid complex formation. Protein is partially unfolded and binds to fatty acids to form protein–lipid complex. Structure of oleic acid is obtained from Protein Data Bank ID: 1GNI.
Fig. 2
Fig. 2. Overview of multiple biological functions of protein–lipid complexes. These biological functions of protein–lipid complexes are exerted by the fatty acid compartment rather than by proteinaceous shell or both protein and fatty acid together.
Fig. 3
Fig. 3. Suggested mechanisms and strategies of the cytotoxic protein–lipid complexes against tumor cells during cell death induction.
Fig. 4
Fig. 4. Structures of oleic, elaidic and stearic acids. OA (cis-9-octadecenoic acid, 18 : 1 cis Δ9) has a boomerang-like shape due to cis double bond that restricts the mobility between C9 and C10. Both elaidic acid (trans-9-octadecenoic acid, 18 : 1 trans Δ9, trans-isomer of OA) and stearic acid (octadecanoic acid, 18 : 1) have a rod-like shape.
Fig. 5
Fig. 5. Overview of the cytotoxic protein–lipid complexes' activities against Gram negative bacteria.

Similar articles

Cited by

References

    1. Håkansson A. Zhivotovsky B. Orrenius S. Sabharwal H. Svanborg C. Proc. Natl. Acad. Sci. U. S. A. 1995;92:8064–8068. doi: 10.1073/pnas.92.17.8064. - DOI - PMC - PubMed
    1. Fischer W. Gustafsson L. Mossberg A. K. Gronli J. Mork S. Bjerkvig R. Svanborg C. Cancer Res. 2004;64:2105–2112. doi: 10.1158/0008-5472.CAN-03-2661. - DOI - PubMed
    1. Gustafsson L. Leijonhufvud I. Aronsson A. Mossberg A. K. Svanborg C. N. Engl. J. Med. 2004;350:2663–2672. doi: 10.1056/NEJMoa032454. - DOI - PubMed
    1. Mossberg A. K. Wullt B. Gustafsson L. Mansson W. Ljunggren E. Svanborg C. Int. J. Cancer. 2007;121:1352–1359. doi: 10.1002/ijc.22810. - DOI - PubMed
    1. Mossberg A. K. Hou Y. Svensson M. Holmqvist B. Svanborg C. J. Urol. 2010;183:1590–1597. doi: 10.1016/j.juro.2009.12.008. - DOI - PubMed